

---

# SANDOZ IN IMMUNOLOGY

## SUPPORT ALONG THE CONTINUUM OF CARE

---



1. European Commission. Consensus Information Paper 2013. What you need to know about Biosimilar Medicinal Products. Available from: <http://ec.europa.eu/DocsRoom/documents/8242/attachments/1/translations/en/renditions/native> [Accessed February 2019]

2. Biosimilar medicines: Overview. European Medicines Agency. Available from: <https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview> [Accessed September 2019]

3. European Commission. Consensus Information Paper 2013. What you need to know about Biosimilar Medicinal Products. Available from: <http://ec.europa.eu/DocsRoom/documents/8242/attachments/1/translations/en/renditions/native> [Accessed February 2019]

4. Information on Biosimilars. FDA. Available from: <https://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/> [Accessed February 2019]

5. Bud E (2007). Penicillin: Triumph & Tragedy. Great Britain: Oxford University Press.

6. Sagi S, et al. J Manag Care Spec Pharm 2017;23(12):1249-1254.



# Biosimilars explained

Biological medicines are produced via living systems (plant or animal cells, bacteria, viruses and yeast)<sup>1</sup>.


These medicines have revolutionized the treatment and prevention of many disabling and life-threatening diseases<sup>1</sup>.

A biosimilar is a biological medicine highly similar to another already approved biological medicine (the 'reference medicine'). Biosimilars are approved according to the same standards of pharmaceutical quality, safety and efficacy that apply to all biological medicines<sup>2</sup>.

**INFLAMMATORY  
BOWEL  
DISEASE**

**PSORIASIS**

**ARTHRITIS**



# Biologics: reference medicines and biosimilars



## A reference and a duplicate key – the same lock and door

Think of a reference medicine and a biosimilar as a reference key and a duplicate key respectively. The result of both keys is the same – they both fit the same lock and open the door. In the same way, an approved biosimilar can be expected to have the same safety and efficacy effects in patients as the reference medicine.<sup>3,4</sup>

## Sandoz in Immunology support along the continuum of care

- ✓ 70 years of biotechnology expertise<sup>5</sup>
- ✓ Nearly 350 million patient days of experience generated<sup>6</sup>
- ✓ Industry-leading portfolio
- ✓ Sandoz biologics are marketed in 86 countries